Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.025 (1.96%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

5 Feb 2020 17:38

RNS Number : 1217C
Genedrive PLC
05 February 2020
 

 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Lisa Miele, a Person Closely Associated with Gino Miele R&D Director and a PDMR, acquired 8,636 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 8.875p per today.

 

Following these purchases, Gino Miele's total beneficial interest is 66,979 Ordinary Shares, 0.2% of the issued share capital of the Company.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Lisa Miele

 

 

2.

Reason for the notification

a.

Position/status

PCA of Gino Miele R&D Director

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

 

 

 

GB00B1VKB244

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

 

Price(s)

Volume(s)

8.875p

8,636

 

d.

Aggregated information

·; Aggregated volume

·; Price

 

 

N/A

 

e.

Date of the transaction

2020-02-05

f.

Place of the transaction

London Stock Exchange, AIM

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

Stanford Capital Partners Limited (Joint Broker)

+44 (0)20 3815 8880

Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAXASEDDEEFA
Date   Source Headline
27th May 20227:00 amRNSBlock listing Interim Review
25th Apr 20229:05 amRNSSecond Price Monitoring Extn
25th Apr 20229:00 amRNSPrice Monitoring Extension
20th Apr 20222:00 pmRNSPrice Monitoring Extension
8th Apr 20224:41 pmRNSSecond Price Monitoring Extn
8th Apr 20224:35 pmRNSPrice Monitoring Extension
4th Apr 20225:13 pmRNSDirector/PDMR Shareholding
4th Apr 202211:05 amRNSSecond Price Monitoring Extn
4th Apr 202211:00 amRNSPrice Monitoring Extension
4th Apr 20229:05 amRNSSecond Price Monitoring Extn
4th Apr 20229:00 amRNSPrice Monitoring Extension
31st Mar 20229:05 amRNSSecond Price Monitoring Extn
31st Mar 20229:00 amRNSPrice Monitoring Extension
29th Mar 202211:06 amRNSSecond Price Monitoring Extn
29th Mar 202211:00 amRNSPrice Monitoring Extension
29th Mar 202210:00 amRNSNICE issues Medtech Innovation Briefing
29th Mar 20227:00 amRNSHalf-year Report
25th Mar 202211:05 amRNSSecond Price Monitoring Extn
25th Mar 202211:00 amRNSPrice Monitoring Extension
24th Mar 20222:00 pmRNSPrice Monitoring Extension
22nd Mar 20224:41 pmRNSSecond Price Monitoring Extn
22nd Mar 20224:36 pmRNSPrice Monitoring Extension
21st Mar 20223:16 pmRNSPALOH study results published in JAMA Pediatrics
21st Mar 20229:05 amRNSSecond Price Monitoring Extn
21st Mar 20229:00 amRNSPrice Monitoring Extension
18th Mar 20224:41 pmRNSSecond Price Monitoring Extn
18th Mar 20224:36 pmRNSPrice Monitoring Extension
18th Mar 20222:05 pmRNSSecond Price Monitoring Extn
18th Mar 20222:00 pmRNSPrice Monitoring Extension
18th Mar 20222:00 pmRNSFirst NHS Deployments of Genedrive System for AIHL
17th Mar 20227:00 amRNSBoard appointment
16th Mar 20224:41 pmRNSSecond Price Monitoring Extn
16th Mar 20224:35 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSFurther re Directorate Change
23rd Feb 20225:00 pmRNSDirector/PDMR Shareholding
23rd Feb 20229:05 amRNSSecond Price Monitoring Extn
23rd Feb 20229:00 amRNSPrice Monitoring Extension
23rd Feb 20227:00 amRNSUpdate on Point of Care Covid Test
15th Feb 20222:01 pmRNSPrice Monitoring Extension
4th Feb 20227:00 amRNSNotice of Results
21st Jan 202211:05 amRNSSecond Price Monitoring Extn
21st Jan 202211:00 amRNSPrice Monitoring Extension
20th Jan 20224:40 pmRNSSecond Price Monitoring Extn
20th Jan 20224:36 pmRNSPrice Monitoring Extension
10th Jan 20229:06 amRNSSecond Price Monitoring Extn
10th Jan 20229:00 amRNSPrice Monitoring Extension
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn
7th Jan 20222:01 pmRNSPrice Monitoring Extension
30th Dec 202111:20 amRNSResult of AGM
30th Dec 20219:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.